In acute myeloid leukemia with MLL1 rearrangement (MLL1r) or mutant NPM1 (mtNPM1), treatment with menin inhibitors (MIs) can induce clinical remission; however, many patients either exhibit resistance or experience relapse, with some acquiring menin mutations. Here, NPM1 is linked to acute myeloid leukemia.